Feiyue Feng
Overview
Explore the profile of Feiyue Feng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun D, Hou H, Feng F, Wu W, Tan J, Xie T, et al.
Exp Hematol Oncol
. 2025 Jan;
14(1):3.
PMID: 39773749
Background: Osimertinib has emerged as a critical element in the treatment landscape following recent clinical trials. Further investigation into the mechanisms driving resistance to Osimertinib is necessary to address the...
2.
Huang Y, Zeng H, Zhang G, Ren F, Yuan Z, Ren J, et al.
Ann Surg Oncol
. 2024 Nov;
32(2):760-770.
PMID: 39586954
Background: The prognostic significance of epidermal growth factor receptor (EGFR) mutations in stage I invasive lung adenocarcinoma (LUAD) remains debated. Improving the lung cancer staging system requires further investigation into...
3.
Chen Z, Wang X, Jin Z, Li B, Jiang D, Wang Y, et al.
NPJ Precis Oncol
. 2024 Mar;
8(1):73.
PMID: 38519580
Tertiary lymphoid structures (TLSs) have been associated with favorable immunotherapy responses and prognosis in various cancers. Despite their significance, their quantification using multiplex immunohistochemistry (mIHC) staining of T and B...
4.
Xu J, Zeng H, Zhang G, Li R, Yuan Z, Ren J, et al.
Thorac Cancer
. 2023 Oct;
14(31):3108-3118.
PMID: 37793977
Background: This study aimed to establish a nomogram for predicting risk of recurrence and provide a model for decision-making between lobectomy and sublobar resection in patients with stage IA lung...
5.
Bie F, Wang Z, Li Y, Guo W, Hong Y, Han T, et al.
Nat Commun
. 2023 Sep;
14(1):6042.
PMID: 37758728
Multimodal epigenetic characterization of cell-free DNA (cfDNA) could improve the performance of blood-based early cancer detection. However, integrative profiling of cfDNA methylome and fragmentome has been technologically challenging. Here, we...
6.
Wu Z, Tan F, Xie Y, Tang W, Wang F, Xu Y, et al.
Cancer Med
. 2023 May;
12(13):14781-14793.
PMID: 37199391
Background: The ability of lung cancer screening to manage pulmonary nodules was limited because of the high false-positive rate in the current mainstream screening method, low-dose computed tomography (LDCT). We...
7.
Sun D, Feng F, Teng F, Xie T, Wang J, Xing P, et al.
Cell Commun Signal
. 2023 Mar;
21(1):48.
PMID: 36869329
Introduction: Dysregulated ARID1A expression is frequently detected in lung adenocarcinoma (LUAD) and mediates significant changes in cancer behaviors and a poor prognosis. ARID1A deficiency in LUAD enhances proliferation and metastasis,...
8.
Liang M, Tang W, Tan F, Zeng H, Guo C, Feng F, et al.
Front Oncol
. 2023 Feb;
13:1103269.
PMID: 36798818
Objectives: This study aimed to identify the computed tomography (CT) features associated with the new International Association for the Study of Lung Cancer (IASLC) three-tiered grading system to improve the...
9.
Du Y, Ma Y, Zhu Q, Fu Y, Li Y, Zhang Y, et al.
Front Med
. 2022 Dec;
17(1):119-131.
PMID: 36525138
Treating patients with esophageal squamous cell carcinoma (ESCC) is challenging due to the high chemoresistance. Growth differentiation factor 15 (GDF15) is crucial in the development of various types of tumors...
10.
Tan F, Bi N, Zhang H, Li R, Wang Z, Duan J, et al.
Lung Cancer
. 2022 Jun;
170:98-104.
PMID: 35749952
Objectives: The newly released eighth edition of the American Joint Committee on Cancer TNM staging system for lung cancer seeks to improve prognostic accuracy but lacks external validation for small...